Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool

FRAUNHOFFER, NICOLAS A.; ABUELAFIA, ANALÍA MEILERMAN; DUSETTI, NELSON; IOVANNA, JUAN

Cancer Communications

John Wiley and Sons Inc

Año: 2022 vol. 42 p. 1028 - 1031

Pancreatic ductal adenocarcinoma (PDAC) is a dismaldisease with a fast evolution and unpredictable treatmentresponse. Nowadays, FOLFIRINOX and gemcitabine are the preferred treatments with a response rateof 33% and 11%, respectively. This poor patient responsehas been associated with an inefficient/non-personalizedtreatment allocation. Consequently, developing a rapidand efficient preclinical tool to test tumor drug sensitivityfor each patient is hugely needed. Biopsy patient-derivedorganoid (PDO) appears to be a promising tool for devel-oping individualized treatments for patients with PDAC.Several PDO-based platforms are in development world-wide as a guide to optimize therapy by directing tailored treatments.